After finishing at $17.73 in the prior trading day, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) closed at $17.41, down -1.80%. In other words, the price has decreased by -$0.32 from its previous closing price. On the day, 1489588 shares were traded.
Ratios:
Our goal is to gain a better understanding of ACAD by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 172.29. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.42. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 12, 2024, Reiterated its Buy rating but revised its target price to $32 from $36 previously.
On March 12, 2024, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $39 to $25.
On January 30, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $40.Robert W. Baird initiated its Outperform rating on January 30, 2024, with a $40 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 08 ’24 when DAVIS STEPHEN sold 26,574 shares for $17.87 per share. The transaction valued at 474,877 led to the insider holds 144,267 shares of the business.
Schneyer Mark C. sold 2,716 shares of ACAD for $48,535 on Apr 08 ’24. The EVP, CHIEF FINANCIAL OFFICER now owns 28,742 shares after completing the transaction at $17.87 per share. On Apr 08 ’24, another insider, Teehan Brendan, who serves as the EVP, COO, HEAD OF COMMERCIAL of the company, sold 2,568 shares for $17.87 each. As a result, the insider received 45,890 and left with 38,796 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 2.87B and an Enterprise Value of 2.49B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.95 while its Price-to-Book (P/B) ratio in mrq is 6.64. Its current Enterprise Value per Revenue stands at 3.43 whereas that against EBITDA is -36.69.
Stock Price History:
Over the past 52 weeks, ACAD has reached a high of $33.99, while it has fallen to a 52-week low of $17.55. The 50-Day Moving Average of the stock is 22.03, while the 200-Day Moving Average is calculated to be 24.93.
Shares Statistics:
The stock has traded on average 1.82M shares per day over the past 3-months and 1.38M shares per day over the last 10 days, according to various share statistics. A total of 164.65M shares are outstanding, with a floating share count of 163.49M. Insiders hold about 0.78% of the company’s shares, while institutions hold 97.03% stake in the company. Shares short for ACAD as of Mar 28, 2024 were 11.2M with a Short Ratio of 6.14, compared to 10.81M on Feb 29, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.80% and a Short% of Float of 9.08%.
Earnings Estimates
Its stock is currently analyzed by 19 different market analysts. On average, analysts expect EPS of $0.05 for the current quarter, with a high estimate of $0.17 and a low estimate of -$0.08, while EPS last year was -$0.27. The consensus estimate for the next quarter is $0.2, with high estimates of $0.32 and low estimates of $0.11.
Analysts are recommending an EPS of between $1.24 and $0.3 for the fiscal current year, implying an average EPS of $0.66. EPS for the following year is $1.29, with 20 analysts recommending between $2.16 and $0.79.
Revenue Estimates
18 analysts predict $208.79M in revenue for the current quarter. It ranges from a high estimate of $223.7M to a low estimate of $201.3M. As of the current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $118.46M, an estimated increase of 76.30% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $241.99M, an increase of 53.30% less than the figure of $76.30% in the same quarter last year. There is a high estimate of $253M for the next quarter, whereas the lowest estimate is $235.9M.
A total of 20 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $989.5M, while the lowest revenue estimate was $940.7M, resulting in an average revenue estimate of $968.28M. In the same quarter a year ago, actual revenue was $726.44M, up 33.30% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $1.09B in the next fiscal year. The high estimate is $1.17B and the low estimate is $993.2M. The average revenue growth estimate for next year is up 13.10% from the average revenue estimate for this year.
